Tenofovir disoproxil fumarate has a substantial efficacy against multidrug-resistant strains of hepatitis B virus

Background & Aims To evaluate the efficacy of tenofovir in chronic hepatitis B (CHB) patients with adefovir resistance (ADF‐R) and suboptimal response to adefovir (ADF‐S). Methods Nucleos(t)ide analogue (NA)‐naïve patients and patients with previous adefovir failure receiving tenofovir therapy f...

Full description

Saved in:
Bibliographic Details
Published in:Liver international 2015-10, Vol.35 (10), p.2265-2274
Main Authors: Baran, Bulent, Soyer, Ozlem Mutluay, Ormeci, Asli Cifcibasi, Gokturk, Suut, Evirgen, Sami, Akyuz, Filiz, Karaca, Cetin, Demir, Kadir, Besisik, Fatih, Onel, Derya, Gulluoglu, Mine, Badur, Selim, Kaymakoglu, Sabahattin
Format: Article
Language:English
Subjects:
adefovir failure
Adolescent
Adult
Aged
Alanine Transaminase
Antiviral Agents - administration & dosage
chronic hepatitis B
DNA, Viral
Drug Resistance, Viral
Female
genotypic resistance
Hepatitis B e Antigens - blood
Hepatitis B virus - drug effects
Hepatitis B virus - genetics
Hepatitis B, Chronic - drug therapy
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Multivariate Analysis
Proportional Hazards Models
Tenofovir - administration & dosage
tenofovir disoproxil fumarate
Treatment Outcome
Viral Load
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background & Aims To evaluate the efficacy of tenofovir in chronic hepatitis B (CHB) patients with adefovir resistance (ADF‐R) and suboptimal response to adefovir (ADF‐S). Methods Nucleos(t)ide analogue (NA)‐naïve patients and patients with previous adefovir failure receiving tenofovir therapy for at least 6 months were included in the study. Biochemical and virological tests were obtained at baseline and 3‐month intervals in the first year and every 6 months thereafter. The primary outcome measure was complete virological response (CVR) (HBVDNA 
ISSN:1478-3223
1478-3231
DOI:10.1111/liv.12831